- Home
- LPA vs MGNX Comparison
LPA vs MGNX Comparison
Compare LPA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- MGNX
- Stock Information
- Founded
- LPA 2013
- MGNX 2000
- Country
- LPA United States
- MGNX United States
- Employees
- LPA N/A
- MGNX N/A
- Industry
- LPA
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- LPA
- MGNX Health Care
- Exchange
- LPA Nasdaq
- MGNX Nasdaq
- Market Cap
- LPA 241.7M
- MGNX 257.3M
- IPO Year
- LPA N/A
- MGNX 2013
- Fundamental
- Price
- LPA $10.00
- MGNX $3.17
- Analyst Decision
- LPA
- MGNX Hold
- Analyst Count
- LPA 0
- MGNX 10
- Target Price
- LPA N/A
- MGNX $7.17
- AVG Volume (30 Days)
- LPA 121.4K
- MGNX 506.1K
- Earning Date
- LPA 02-14-2025
- MGNX 11-05-2024
- Dividend Yield
- LPA N/A
- MGNX N/A
- EPS Growth
- LPA N/A
- MGNX N/A
- EPS
- LPA N/A
- MGNX N/A
- Revenue
- LPA $44,311,428.00
- MGNX $141,329,000.00
- Revenue This Year
- LPA N/A
- MGNX $174.73
- Revenue Next Year
- LPA N/A
- MGNX N/A
- P/E Ratio
- LPA N/A
- MGNX N/A
- Revenue Growth
- LPA 22.46
- MGNX 16.68
- 52 Week Low
- LPA $6.00
- MGNX $2.95
- 52 Week High
- LPA $525.00
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- MGNX 41.22
- Support Level
- LPA N/A
- MGNX $3.10
- Resistance Level
- LPA N/A
- MGNX $3.45
- Average True Range (ATR)
- LPA 0.00
- MGNX 0.20
- MACD
- LPA 0.00
- MGNX -0.01
- Stochastic Oscillator
- LPA 0.00
- MGNX 17.24
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).